Under nonstudy conditions or in regular clinical practice, the risk of diabetic ketoacidosis exists; therefore, the prescription of SGLT-2 inhibitors in individuals with type 1 diabetes is not particularly advised [29]. Here, SLC5A2 is linked to type 1 diabetes mellitus.